JP2009540314A - 筋障害診断方法 - Google Patents
筋障害診断方法 Download PDFInfo
- Publication number
- JP2009540314A JP2009540314A JP2009514827A JP2009514827A JP2009540314A JP 2009540314 A JP2009540314 A JP 2009540314A JP 2009514827 A JP2009514827 A JP 2009514827A JP 2009514827 A JP2009514827 A JP 2009514827A JP 2009540314 A JP2009540314 A JP 2009540314A
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- statin
- myopathy
- standard
- profile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000021642 Muscular disease Diseases 0.000 title claims abstract description 59
- 201000009623 Myopathy Diseases 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims abstract description 40
- 238000003745 diagnosis Methods 0.000 title claims abstract description 6
- 150000002632 lipids Chemical class 0.000 claims abstract description 119
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims abstract description 74
- 230000014509 gene expression Effects 0.000 claims abstract description 29
- 239000003550 marker Substances 0.000 claims abstract description 22
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 15
- 210000003205 muscle Anatomy 0.000 claims abstract description 13
- 239000012472 biological sample Substances 0.000 claims abstract description 10
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 5
- 238000004458 analytical method Methods 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 20
- 239000000090 biomarker Substances 0.000 claims description 19
- 230000037361 pathway Effects 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 101150104383 ALOX5AP gene Proteins 0.000 claims 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 claims 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 13
- 238000002405 diagnostic procedure Methods 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 26
- 229960002855 simvastatin Drugs 0.000 description 26
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 18
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 18
- 229960005370 atorvastatin Drugs 0.000 description 18
- 239000000523 sample Substances 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 14
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 13
- 230000037356 lipid metabolism Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 102000004420 Creatine Kinase Human genes 0.000 description 9
- 108010042126 Creatine kinase Proteins 0.000 description 9
- 238000004949 mass spectrometry Methods 0.000 description 7
- 150000001840 cholesterol esters Chemical class 0.000 description 6
- 210000002027 skeletal muscle Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 230000037353 metabolic pathway Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 4
- -1 sterol esters Chemical class 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000029549 Muscle injury Diseases 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000002705 metabolomic analysis Methods 0.000 description 3
- 208000013465 muscle pain Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 150000002066 eicosanoids Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000007417 hierarchical cluster analysis Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000001431 metabolomic effect Effects 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 150000002759 monoacylglycerols Chemical class 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940035936 ubiquinone Drugs 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 1
- ASWBNKHCZGQVJV-HSZRJFAPSA-O 1-O-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-HSZRJFAPSA-O 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- PUDHBQQGURLBGJ-IVFHWKNFSA-N 1-arachidonoyl-2-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC PUDHBQQGURLBGJ-IVFHWKNFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 101150029429 38 gene Proteins 0.000 description 1
- 102100022278 Arachidonate 5-lipoxygenase-activating protein Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100031611 Collagen alpha-1(III) chain Human genes 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000755875 Homo sapiens Arachidonate 5-lipoxygenase-activating protein Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000993285 Homo sapiens Collagen alpha-1(III) chain Proteins 0.000 description 1
- 101000584362 Homo sapiens Myosin-binding protein H Proteins 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 102100030626 Myosin-binding protein H Human genes 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 102100021482 Solute carrier family 49 member A3 Human genes 0.000 description 1
- 101710113279 Solute carrier family 49 member A3 Proteins 0.000 description 1
- FBFWDBGUSMGXPI-UHFFFAOYSA-N TG(17:0/17:0/17:0) Chemical compound CCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCC FBFWDBGUSMGXPI-UHFFFAOYSA-N 0.000 description 1
- AZRNEVJSOSKAOC-VPHBQDTQSA-N [[(2r,3s,5r)-5-[5-[(e)-3-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoylamino]prop-1-enyl]-2,4-dioxopyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(\C=C\CNC(=O)CCCCCNC(=O)CCCC[C@H]2[C@H]3NC(=O)N[C@H]3CS2)=C1 AZRNEVJSOSKAOC-VPHBQDTQSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000012615 high-resolution technique Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81260206P | 2006-06-12 | 2006-06-12 | |
| US87249506P | 2006-12-04 | 2006-12-04 | |
| PCT/FI2007/050344 WO2007144467A1 (en) | 2006-06-12 | 2007-06-12 | Diagnostic method for myopathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009540314A true JP2009540314A (ja) | 2009-11-19 |
| JP2009540314A5 JP2009540314A5 (enExample) | 2010-07-29 |
Family
ID=38831439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009514827A Pending JP2009540314A (ja) | 2006-06-12 | 2007-06-12 | 筋障害診断方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US7611902B2 (enExample) |
| EP (1) | EP2029771A4 (enExample) |
| JP (1) | JP2009540314A (enExample) |
| WO (1) | WO2007144467A1 (enExample) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013525764A (ja) * | 2010-04-16 | 2013-06-20 | ザ・ジョンズ・ホプキンス・ユニバーシティ | ミオパチーを特性化するための組成物及び方法 |
| JP2013527449A (ja) * | 2010-05-05 | 2013-06-27 | ゾラ バイオサイエンシーズ オサケ ユキチュア | アテローム性動脈硬化症及び心脈管系疾患のリピドームバイオマーカー |
| JP2013531238A (ja) * | 2010-06-20 | 2013-08-01 | ゾラ バイオサイエンシーズ オサケ ユキチュア | 冠状動脈疾患高リスク患者を認定するリピドームバイオマーカー |
| JP2014513286A (ja) * | 2011-04-08 | 2014-05-29 | ゾラ バイオサイエンシーズ オサケ ユキチュア | スタチン誘発性筋毒性の高感度検出のためのバイオマーカー |
| JP2016001183A (ja) * | 2010-01-29 | 2016-01-07 | メタノミクス ゲーエムベーハー | 被験体において心不全を診断するための手段及び方法 |
| JP2016191718A (ja) * | 2016-07-27 | 2016-11-10 | ゾラ バイオサイエンシーズ オサケ ユキチュア | スタチン誘発性筋毒性の高感度検出のためのバイオマーカー |
| US9541565B2 (en) | 2011-04-08 | 2017-01-10 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
| JP2017009329A (ja) * | 2015-06-17 | 2017-01-12 | 花王株式会社 | 運動機能の判定用マーカー |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8137977B2 (en) * | 2006-04-24 | 2012-03-20 | Children's Hospital & Research Center At Oakland | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
| CA2800023A1 (en) * | 2010-06-01 | 2011-12-08 | Metanomics Health Gmbh | Means and methods for diagnosing pancreatic cancer in a subject |
| DK2508895T3 (en) * | 2011-04-08 | 2015-10-19 | Zora Biosciences Oy | BIOMARKERS FOR SENSITIVE DETECTION OF STATIN-INDUCED MUSCLE TOXICITY |
| RU2641038C1 (ru) * | 2017-03-06 | 2018-01-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Способ диагностики врожденной миопатии центрального стержня |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050037946A1 (en) * | 2003-01-13 | 2005-02-17 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 or 2419 |
| JP2005512516A (ja) * | 2001-09-24 | 2005-05-12 | メルク エンド カムパニー インコーポレーテッド | スタチン薬物の組合せのスクリーニング方法および選択方法 |
| JP2006509516A (ja) * | 2002-12-13 | 2006-03-23 | セロゴ | 培地組成物、培養方法、得られた筋芽細胞、および該細胞の使用方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1417629B1 (en) * | 2001-07-06 | 2008-02-20 | Lipomics Technologies, Inc. | Generating, viewing, interpreting, and utilizing a quantitative database of metabolites |
| CA2459508A1 (en) * | 2001-09-24 | 2003-04-03 | Lipomics Technologies, Inc. | Methods of using quantitative lipid metabolome data |
| AU2003225752A1 (en) * | 2002-03-12 | 2003-09-29 | Paul S. Phillips | Method of diagnosing statin myopathy |
| US20070202518A1 (en) * | 2005-11-18 | 2007-08-30 | Genomas, Inc. | Physiogenomic method for predicting statin injury to muscle and muscle side effects |
| WO2007061995A2 (en) * | 2005-11-21 | 2007-05-31 | Novartis Ag | Biomarkers for statin-induced myopathy or rhabdomyolysis |
-
2007
- 2007-06-12 EP EP07765914A patent/EP2029771A4/en not_active Withdrawn
- 2007-06-12 US US11/761,427 patent/US7611902B2/en not_active Expired - Fee Related
- 2007-06-12 JP JP2009514827A patent/JP2009540314A/ja active Pending
- 2007-06-12 WO PCT/FI2007/050344 patent/WO2007144467A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005512516A (ja) * | 2001-09-24 | 2005-05-12 | メルク エンド カムパニー インコーポレーテッド | スタチン薬物の組合せのスクリーニング方法および選択方法 |
| JP2006509516A (ja) * | 2002-12-13 | 2006-03-23 | セロゴ | 培地組成物、培養方法、得られた筋芽細胞、および該細胞の使用方法 |
| US20050037946A1 (en) * | 2003-01-13 | 2005-02-17 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 or 2419 |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017167158A (ja) * | 2010-01-29 | 2017-09-21 | メタノミクス ゲーエムベーハー | 被験体において心不全を診断するための手段及び方法 |
| JP2016001183A (ja) * | 2010-01-29 | 2016-01-07 | メタノミクス ゲーエムベーハー | 被験体において心不全を診断するための手段及び方法 |
| JP2013525764A (ja) * | 2010-04-16 | 2013-06-20 | ザ・ジョンズ・ホプキンス・ユニバーシティ | ミオパチーを特性化するための組成物及び方法 |
| JP2013527449A (ja) * | 2010-05-05 | 2013-06-27 | ゾラ バイオサイエンシーズ オサケ ユキチュア | アテローム性動脈硬化症及び心脈管系疾患のリピドームバイオマーカー |
| US12025623B2 (en) | 2010-05-05 | 2024-07-02 | Zora Biosciences Oy | Lipidomic biomarkers for atherosclerosis and cardiovascular disease |
| US10551394B2 (en) | 2010-05-05 | 2020-02-04 | Zora Biosciences Oy | Lipidomic biomarkers for atherosclerosis and cardiovascular disease |
| US9046538B2 (en) | 2010-05-05 | 2015-06-02 | Zora Biosciences Oy | Lipidomic biomarkers for atherosclerosis and cardiovascular disease |
| US9459264B2 (en) | 2010-05-05 | 2016-10-04 | Zora Biosciences Oy | Lipidomic biomarkers for atherosclerosis and cardiovascular disease |
| US9857386B2 (en) | 2010-05-05 | 2018-01-02 | Zora Biosciences Oy | Lipidomic biomarkers for atherosclerosis and cardiovascular disease |
| US9201080B2 (en) | 2010-06-20 | 2015-12-01 | Zora Biosciences Oy | Lipidomic biomarkers for identification of high-risk coronary artery disease patients |
| JP2017129592A (ja) * | 2010-06-20 | 2017-07-27 | ゾラ バイオサイエンシーズ オサケ ユキチュア | 冠状動脈疾患高リスク患者を認定するリピドームバイオマーカー |
| US9841431B2 (en) | 2010-06-20 | 2017-12-12 | Zora Biosciences Oy | Lipidomic biomarkers for identification of high-risk coronary artery disease patients |
| US10261101B2 (en) | 2010-06-20 | 2019-04-16 | Zora Biosciences Oy | Lipidomic biomarkers for identification of high-risk coronary artery disease patients |
| US10955427B2 (en) | 2010-06-20 | 2021-03-23 | Zora Biosciences Oy | Lipidomic biomarkers for identification of high-risk coronary artery disease patients |
| JP2013531238A (ja) * | 2010-06-20 | 2013-08-01 | ゾラ バイオサイエンシーズ オサケ ユキチュア | 冠状動脈疾患高リスク患者を認定するリピドームバイオマーカー |
| US12270816B2 (en) | 2010-06-20 | 2025-04-08 | Zora Biosciences Oy | Lipidomic biomarkers for identification of high-risk coronary artery disease patients |
| US9664698B2 (en) | 2011-04-08 | 2017-05-30 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
| US9541565B2 (en) | 2011-04-08 | 2017-01-10 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
| JP2014513286A (ja) * | 2011-04-08 | 2014-05-29 | ゾラ バイオサイエンシーズ オサケ ユキチュア | スタチン誘発性筋毒性の高感度検出のためのバイオマーカー |
| JP2017009329A (ja) * | 2015-06-17 | 2017-01-12 | 花王株式会社 | 運動機能の判定用マーカー |
| JP2016191718A (ja) * | 2016-07-27 | 2016-11-10 | ゾラ バイオサイエンシーズ オサケ ユキチュア | スタチン誘発性筋毒性の高感度検出のためのバイオマーカー |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080003684A1 (en) | 2008-01-03 |
| EP2029771A4 (en) | 2010-08-04 |
| US7611902B2 (en) | 2009-11-03 |
| EP2029771A1 (en) | 2009-03-04 |
| WO2007144467A1 (en) | 2007-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009540314A (ja) | 筋障害診断方法 | |
| Liesenfeld et al. | Metabolomics and transcriptomics identify pathway differences between visceral and subcutaneous adipose tissue in colorectal cancer patients: the ColoCare study | |
| Gorden et al. | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic | |
| Li et al. | Profile of pathogenic proteins and microRNAs in plasma-derived extracellular vesicles in Alzheimer’s disease: A pilot study | |
| Mutemberezi et al. | Oxysterol levels and metabolism in the course of neuroinflammation: insights from in vitro and in vivo models | |
| Zengi et al. | Urinary 8-hydroxy-2′-deoxyguanosine level and plasma paraoxonase 1 activity with Alzheimer’s disease | |
| JP6873490B2 (ja) | 糖尿病関連バイオマーカーおよび糖尿病関連状態の処置 | |
| EP2930512A2 (en) | Biomarkers for fatty liver disease and methods using the same | |
| AU2016202883A1 (en) | Methods of detecting neurological or neuropsychiatric diseases or conditions | |
| JP2011529344A (ja) | アルツハイマー病の刺激誘発ゲノムプロフィールマーカー | |
| CN111826466B (zh) | 乙型肝炎感染患者或携带者外泌体miRNA分子标志物组合及筛查试剂盒 | |
| US20150008314A1 (en) | Diagnostic and prognostic biomarkers for cancer | |
| AU2012351963A1 (en) | Identification of two novel biomarkers for Niemann-Pick disease type C | |
| CN102597781B (zh) | 判定高功能自闭症的发病危险度的方法及标记物 | |
| CN101522910A (zh) | 肌病的诊断方法 | |
| EP3714273A1 (en) | Methods for prediction and early detection of diabetes | |
| JP2022166259A (ja) | 疾患診断、化学予防、および処置のための超長鎖ジカルボン酸の同定および使用 | |
| US20080020472A1 (en) | Method for detecting an inflammatory disease or cancer | |
| WO2018228875A1 (en) | Micro-rna biomarkers of blood-brain barrier dysfunction | |
| CN119673477A (zh) | 一种利用小鼠模型研究高脂饮食对老年健康影响机制的研究方法 | |
| US7491504B2 (en) | Method for detecting ovarian cancer | |
| JP7650375B2 (ja) | アシルカルニチン代謝体を含む口腔癌診断用のバイオマーカー組成物 | |
| EP3171173A1 (en) | Method of diagnosis of a thoracic aortic aneurysm | |
| CN114324902B (zh) | 胆固醇稳态的生物标志物及其应用 | |
| CN116926189B (zh) | 外泌体lncRNA在检测药源性心肌损伤中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100611 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100611 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110915 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110927 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120313 |